Uveitis News and Research

RSS

Uveitis is an inflammation of the uvea. The uvea is the front part of the eye. It includes the iris, which is the colored part of the eye, and the parts right next to and behind the iris. Uveitis may hurt a lot of parts of the eye. It may last as long as six weeks, or it may last a shorter time.

Apitope's ATX-F8-117 granted FDA Orphan Drug Designation for treatment of haemophilia A patients

Apitope, the drug discovery and development company focused on disease-modifying treatments that reinstate immune tolerance, announced today that pre-clinical product candidate ATX-F8-117 has been granted Orphan Drug Status by the US Food and Drug Administration for the prevention or treatment of inhibitors in haemophilia A patients with inhibitors or at the risk of producing inhibitors.

9 Jun 2015

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

1 Jun 2015

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Arnaud Foussat, VP Research and New Products, TxCell, will deliver two presentations at the 21st Annual Meeting of the International Society of Cellular Therapy, May 27-30, 2015, in Las Vegas, Nevada, US.

30 May 2015

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

TxCell SA, a biotechnology company developing innovative, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that activity and tolerance data for its second lead product Col-Treg were presented through a poster presentation at the 2015 ARVO Annual Meeting, May 3-7, 2015, in Denver, Colorado, US.

5 May 2015

TxCell to present at upcoming US and French investment conferences

Damian Marron, CEO, TxCell, will present at the Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day, New York, March 25, 2015. In addition, Damian Marron will also participate at the Portzamparc PEA-PME Forum, Paris, April 1, 2015.

24 Mar 2015

TxCell invited to speak at largest US meeting for investors in emerging growth companies

In the presentation, Damian Marron will provide an overview of TxCell and its personalized T cell immunotherapy platform ASTrIA. Additional details will also be provided to institutional investors in one on one meetings at the conference.

27 Feb 2015

TxCell to highlight success factors in cell therapy research at Cell & Gene Therapy Forum 2015

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present at the Cell & Gene Therapy Forum 2015, January 26 - 28, 2015 at Grand Hayatt in Washington DC, United States.

23 Jan 2015

EC grants orphan drug designation to TxCell's Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis.

18 Dec 2014

Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that the European Medicines Agency Committee for Orphan Medicinal Products has granted orphan medicinal product designation to ATX-F8-117 for the treatment of haemophilia A.

25 Nov 2014

TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that TxCell researchers have achieved positive results for Col-Treg, its second product candidate from its ASTrIA platform, in a model of autoimmune uveitis, a leading cause of blindness with very limited treatment options.

28 Oct 2014

TxCell to provide overview of T cellular therapy at 7th National Bio-Therapy Conference

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present on T cellular therapy for autoimmune diseases at the 7th National Bio-Therapy Conference, October 24-26, 2014 at Great Tang Hotel, Shanghai, China.

16 Oct 2014

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy.

19 Aug 2014

Researchers find unique cell type that can protect against uveitis

Researchers at the National Eye Institute (NEI) have found a unique cell type that, in tests on mice, can protect against uveitis—a group of inflammatory diseases that affect the eye and can cause vision loss.

1 Jul 2014

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

23 Jun 2014

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that it has started preclinical development of its novel peptide therapy ATX-GD-459 for the treatment of Graves' disease.

19 Jun 2014

EMA grants Advanced Therapy Medicinal Product classification for TxCell's Col-Treg

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Col-Treg, its second therapeutic candidate from its ASTrIA platform, has been granted Advanced Therapy Medicinal Product (ATMP) classification by the Committee for Advanced Therapies (CAT) of the European Medicines Agency.

22 May 2014

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie announced today that the U.S. Food and Drug Administration has granted HUMIRA orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye.

21 May 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.

6 May 2014

U.Va. researchers named recipients of 2013 Hartwell Individual Biomedical Research Awards

University of Virginia neurologist Dr. Erin Pennock Foff, biologist Sarah Kucenas and biomedical engineer Shayn Peirce-Cotter have been named recipients of 2013 Hartwell Individual Biomedical Research Awards to benefit children of the United States. Each scientist will receive $100,000 in direct annual research support from The Hartwell Foundation for three years.

19 Apr 2014

Santen announces Phase III results of sirolimus intravitreal injections in non-infectious posterior segment uveitis patients

Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double‐masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.

From Santen Pharmaceutical Co., Ltd. 7 Apr 2014